Department of Clinical Nutrition, School of Nutritional Science, Mashhad University of Medical Science, Mashhad, Iran.
Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Clin Nutr ESPEN. 2021 Feb;41:110-117. doi: 10.1016/j.clnesp.2020.10.021. Epub 2020 Nov 19.
Growing attention has been paid to use the combination of magnesium and vitamin E, which might improve metabolic profiles in patients with metabolic diseases. Consequently, we conducted a meta-analysis of published randomized controlled trials (RCTs) to systematically analyze the effects of magnesium and vitamin E co-supplementation on some cardiovascular risk factors in patients with metabolic disorders.
We searched the National Library of PubMed, Scopus, Web of Science, the Cochrane library and Embase databases for studies published before February 2020 and included controlled trials in which used mentioned intervention. Finally, we extracted 4 trials satisfying our selection criteria. Two reviewers selected studies independently of each other and if they disagreed, was asked a third reviewer. The risk of bias of individual studies was assessed using the Cochrane Collaboration risk of bias tool. Data were pooled using the random-effects method and were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI).
A total of 4 studies meet the eligibility criteria. 119 individuals allocated to intervention and 118 participants allocated to control group. Our meta-analysis indicated that the co-supplementation with magnesium and vitamin E resulted in a significant decrease in FPG, Insulin, HOMA-IR, TG, TC, and LDL-C in comparison with placebo. The co-supplementation with magnesium and vitamin E had no significant effects on the body weight, BMI, and HDL. However, there were no significant heterogeneity for all of the variables except for FPG (I = 56.0%, P = 0.103) and TG (I = 80.7%, P = 0.006).
Our meta-analysis indicated that the co-supplementation with magnesium and vitamin E resulted in a significant decrease in FPG, Insulin, HOMA-IR, TG, LDL-C. Moreover, no significant effects on the body weight, BMI and HDL were observed. However, the glycemic-improving properties of magnesium and vitamin E co-supplementation were small and may not reach clinical importance.
人们越来越关注镁和维生素 E 的联合使用,因为它可能改善代谢性疾病患者的代谢谱。因此,我们进行了一项荟萃分析,以系统评估镁和维生素 E 联合补充对代谢紊乱患者某些心血管危险因素的影响。
我们检索了国家医学图书馆的 PubMed、Scopus、Web of Science、Cochrane 图书馆和 Embase 数据库,以获取截至 2020 年 2 月之前发表的研究,并纳入使用上述干预措施的对照试验。最后,我们提取了符合我们选择标准的 4 项研究。两位评审员独立选择研究,如果意见不一致,则请第三位评审员参与。使用 Cochrane 协作风险偏倚工具评估个体研究的风险偏倚。使用随机效应方法汇总数据,并表示为加权均数差(WMD)和 95%置信区间(CI)。
共有 4 项研究符合入选标准。119 名参与者被分配到干预组,118 名参与者被分配到对照组。我们的荟萃分析表明,与安慰剂相比,镁和维生素 E 联合补充可显著降低 FPG、胰岛素、HOMA-IR、TG、TC 和 LDL-C。镁和维生素 E 联合补充对体重、BMI 和 HDL 没有显著影响。然而,除了 FPG(I=56.0%,P=0.103)和 TG(I=80.7%,P=0.006)外,所有变量的异质性均不显著。
我们的荟萃分析表明,镁和维生素 E 联合补充可显著降低 FPG、胰岛素、HOMA-IR、TG、LDL-C。此外,对体重、BMI 和 HDL 没有显著影响。然而,镁和维生素 E 联合补充对血糖的改善作用较小,可能达不到临床意义。